Class II · Moderate risk
Clozapine Tablets USP
Microbial Contamination of Non-Sterile Products
FDA Drug Recalls
14,806 recalls, newest first
Class II · Moderate risk
Phenobarbital Tablets USP
Labeling: Label Mixup; potentially mislabeled
Class II · Moderate risk
Amitriptyline HCL Tablets
Labeling: Label Mixup; potentially mislabeled
Class II · Moderate risk
Phenobarbital Tablets USP
Labeling: Label Mixup; potentially mislabeled
Class II · Moderate risk
Phenobarbital Tablets USP
Labeling: Label Mixup; potentially mislabeled
Class I · High risk
Phenobarbital Tablets USP
Labeling: Label Mixup; potentially mislabeled
Class I · High risk
Phenobarbital Tablets USP
Labeling: Labeled Error on Declared Strength; report of a 1000 ct bottle labeled as Phenobarbital 15 mg tablets actually contained 30 mg tablets
Class III · Low risk
IC-Green (indocyanine green for injection, USP)
Product is being recalled due to low pH value.
Class II · Moderate risk
Estradiol 6 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 10 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 12.5 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 15 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 18 mg pellet
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 20 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 22 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Estradiol 25 mg pellet 99.5% Estradiol USP
CGMP deviations- Lack of Quality Assurance
Class II · Moderate risk
Shield and Protect Moisture Barrier Cream
GMP Deviations; product may not meet cGMP requirements
Class I · High risk
LabidaMAX Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
ZRECT for Women Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
ENHANCEROL Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
BIGnHARD Male Enhancement Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
ZDaily Daily Testosterone and Llibido Booster Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
TORNADO Male Enhancement Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
RECTALIS Male Enhancement Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class I · High risk
Xrect Male Enhancement Herbal Dietary Supplement Capsules
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin